A novel probiotic, Lactobacillus johnsonii 456, resists acid and can persist in the human gut beyond the initial ingestion period

Gut Microbes

Volumn 10, Issue 4, 2019, Pages 458-480

  Davoren, Michael J ^a   Liu, Jared ^b   Castellanos, Jocelyn ^a   Rodríguez Malavé, Norma I ^c   Schiestl, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

bacteria; Gut microbiota; lactobacillus; microbiology; probiotics

Indexed keywords

BACTERIOCIN; BILE ACID; DNA 16S; PROBIOTIC AGENT; BACTERIAL PROTEIN; YOGHURT;

ACID TOLERANCE; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ADHERENCE; BILE ACID TOLERANCE; CACO-2 CELL LINE; CELL ADHESION ASSAY; CELL COUNTING; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DNA SEQUENCE; ENZYME INHIBITION ASSAY; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; GENE SEQUENCE; GENOME ANALYSIS; GENOMICS; GOBLET CELL; HUMAN; HUMAN CELL; INGESTION; INTESTINE; INTESTINE EPITHELIUM; LACTOBACILLUS CASEI; LACTOBACILLUS JOHNSONII; LACTOBACILLUS RHAMNOSUS; LS174T CELL LINE; MONOLAYER ADHESION ASSAY; MOUSE; NONHUMAN; PATHOGEN ADHESION INHIBITION ASSAY; PH; PHYLOGENETIC TREE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALMONELLA ENTERICA; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH ACID; STREPTOCOCCUS THERMOPHILUS; WHOLE GENOME SEQUENCING; ANTIBIOSIS; BACTERIAL GENOME; GENETIC VARIATION; GENETICS; METABOLISM; MICROBIOLOGY; PHYLOGENY; PHYSIOLOGY; TUMOR CELL LINE;

ANTIBIOSIS; BACTERIAL ADHESION; BACTERIAL PROTEINS; BILE ACIDS AND SALTS; CACO-2 CELLS; CELL LINE, TUMOR; GASTRIC ACID; GASTROINTESTINAL TRACT; GENETIC VARIATION; GENOME, BACTERIAL; HUMANS; LACTOBACILLUS JOHNSONII; PHYLOGENY; PROBIOTICS; YOGURT;

EID: 85059034570     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.1080/19490976.2018.1547612     Document Type: Article

References (110)

1. Ciorba MA., A gastroenterologist’s guide to probiotics. Clin Gastroenterol Hepatol. 2012;10(9):960–968.
2. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13(4):260–270. doi: 10.1038/nrg3182.
3. Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. J Gastroenterol. 2015;50(5):495–507. doi: 10.1007/s00535-015-1064-1.
4. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268–1273. doi: 10.1126/science.1223490.
5. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer R-J. The role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104–119. doi: 10.1111/j.1365-2036.2007.03562.x.
6. LeBlanc JG, Chain F, Martín R, Bermúdez-Humarán LG, Courau S, Langella P. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb Cell Fact. 2017;16(1):79. doi: 10.1186/s12934-017-0691-z.
7. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project: exploring the microbial part of ourselves in a changing world. Nature. 2007;449(7164):804. doi: 10.1038/nature06244.
8. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480–484. doi: 10.1038/nature07540.
9. Jones ML, Martoni CJ, Ganopolsky JG, Labbé A, Prakash S. The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention. Expert Opin Biol Ther. 2014;14(4):467–482. doi: 10.1517/14712598.2014.880420.
10. Hartstra AV, Bouter KEC, Bäckhed F, Nieuwdorp M. Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care. 2015;38(1):159–165. doi: 10.2337/dc14-0769.
11. Foster JA, Neufeld K-AM. Gut–brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013;36(5):305–312. doi: 10.1016/j.tins.2013.01.005.
12. Yamamoto ML, Maier I, Dang AT, Berry D, Liu J, Ruegger PM, Yang J-I, Soto PA, Presley LL, Reliene R, et al. Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res. 2013;73(14):4222–4232. doi: 10.1158/0008-5472.CAN-13-0022.
13. Zocco M, DAL VERME LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(11):1567–1574. doi: 10.1111/apt.2006.23.issue-11.
14. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51(3):405–409.
15. Ghouri YA, David MR, Erik FR, Joseph TK, Katherine AJ, Andrew WD. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473.
16. Di Cerbo A, Palmieri B. The market of probiotics. Pak J Pharm Sci. 2015;28(6):2199–2206.
17. Doron S, Hibberd PL, Goldin B, Thorpe C, McDermott L, Snydman DR. Effect of Lactobacillus rhamnosus GG administration on vancomycin-resistant enterococcus colonization in adults with comorbidities. Antimicrob Agents Chemother. 2015;59(8):4593–4599. doi: 10.1128/AAC.00300-15.
18. Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, DeVos M, Enslen M, Paintin M, Franchimont D. Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after ileo‐caecal resection. Inflamm Bowel Dis. 2007;13(2):135–142. doi: 10.1002/ibd.20063.
19. Loftus EV, Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–1517.
20. Kotloff KL. The burden and etiology of diarrheal illness in developing countries. Pediatr Clin. 2017;64(4):799–814. doi: 10.1016/j.pcl.2017.03.006.
21. Servin AL, Coconnier M-H. Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. Best Pract Res Clin Gastroenterol. 2003;17(5):741–754. doi: 10.1016/S1521-6918(03)00052-0.
22. Barefoot SF, Klaenhammer TR. Detection and activity of lactacin B, a bacteriocin produced by Lactobacillus acidophilus. Appl Environ Microbiol. 1983;45(6):1808–1815.
23. Ocaña VS, Nader-Macías ME. Production of antimicrobial substances by lactic acid bacteria II: screening bacteriocin-producing strains with probiotic purposes and characterization of a Lactobacillus bacteriocin. In: Public Health Microbiology: Methods and Protocols. New York: Humana Press; 2004. p. 347–353.
24. Midolo P, Lambert JR, Hull R, Luo F, Grayson ML. In vitro inhibition of helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol. 1995;79(4):475–479.
25. Isobe H, Nishiyama A, Takano T, Higuchi W, Nakagawa S, Taneike I, Fukushima Y, Yamamoto T. Reduction of overall helicobacter pylori colonization levels in the stomach of Mongolian gerbil by Lactobacillus johnsonii La1 (LC1) and its in vitro activities against H. pylori motility and adherence. Biosci Biotechnol Biochem. 2012;76(4):850–852. doi: 10.1271/bbb.110921.
26. Humen MA, De Antoni GL, Benyacoub J, Costas ME, Cardozo MI, Kozubsky L, Saudan K-Y, Boenzli-Bruand A, Blum S, Schiffrin EJ, et al. Lactobacillus johnsonii La1 antagonizes Giardia intestinalis in vivo. Infect Immun. 2005;73(2):1265–1269. doi: 10.1128/IAI.73.2.1265-1269.2005.
27. La Ragione R, Narbad A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii FI9785 for use as a defined competitive exclusion agent against bacterial pathogens in poultry. Lett Appl Microbiol. 2004;38(3):197–205.
28. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev. 2003;16(4):658–672.
29. Mileti E, Matteoli G, Iliev ID, Rescigno M, Fritz JH. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One. 2009;4(9):e7056. doi: 10.1371/journal.pone.0007056.
30. Klaenhammer TR. Probiotic bacteria: today and tomorrow. J Nutr. 2000;130(2):415S–416S. doi: 10.1093/jn/130.2.415S.
31. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol. 2014;11(8):506–514. doi: 10.1038/nrgastro.2014.66.
32. Brassart D, Brassart D, Neeser JR, Michetti P, Servin AL. The selection of dairy bacterial strains with probiotic properties based on their adhesion to human intestinal epithelial cells. In: Proceedings Lactic; Adria Normandie, Caen, France; 1994. p. 94.
33. Salminen S, Laine M, Vonwright A, Vuopio-Varkila J, Korhonen T, Mattila-Sandholm T. Development of selection criteria for probiotic strains to assess their potential in functional foods: a Nordic and European approach. Biosci Microflora. 1996;15(2):61–67. doi: 10.12938/bifidus1996.15.61.
34. Jung T-H, Park JH, Jeon W-M, Han K-S. Butyrate modulates bacterial adherence on LS174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway. Nutr Res Pract. 2015;9(4):343–349. doi: 10.4162/nrp.2015.9.4.343.
35. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. doi: 10.1371/journal.pbio.1002533.
36. Větrovský T, Baldrian P. The variability of the 16S rRNA gene in bacterial genomes and its consequences for bacterial community analyses. PLoS One. 2013;8(2):e57923. doi: 10.1371/journal.pone.0057923.
37. Wu X, Zhao C, Guo Z, Hao Y, Li J, Shi H, Sun Y. Genome sequence of Lactobacillus johnsonii strain W1, isolated from mice. Genome Announc. 2016;4(3):e00561–16. doi: 10.1128/genomeA.00561-16.
38. Buhnik-Rosenblau K, Matsko-Efimov V, Jung M, Shin H, Danin-Poleg Y, Kashi Y. Indication for co-evolution of Lactobacillus johnsonii with its hosts. BMC Microbiol. 2012;12(1):149. doi: 10.1186/1471-2180-12-149.
39. Kailasapathy K, Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and bifidobacterium spp. Immunol Cell Biol. 2000;78(1):80–88. doi: 10.1046/j.1440-1711.2000.00886.x.
40. Charteris W, Kelly PM, Morelli L, Collins JK. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. J Appl Microbiol. 1998;84(5):759–768.
41. Mudie DM, Murray K, Hoad CL, Pritchard SE, Garnett MC, Amidon GL, Gowland PA, Spiller RC, Amidon GE, Marciani L. Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm. 2014;11(9):3039–3047. doi: 10.1021/mp500210c.
42. Prasad J, Gill H, Smart J, Gopal PK. Selection and characterisation of Lactobacillus and bifidobacterium strains for use as probiotics. Int Dairy J. 1998;8(12):993–1002. doi: 10.1016/S0958-6946(99)00024-2.
43. Liong M, Shah N. Acid and bile tolerance and cholesterol removal ability of lactobacilli strains. J Dairy Sci. 2005;88(1):55–66. doi: 10.3168/jds.S0022-0302(05)72662-X.
44. Hassanzadazar H, Ehsani A, Mardani K, Hesari J. Investigation of antibacterial, acid and bile tolerance properties of lactobacilli isolated from Koozeh cheese. In: Veterinary research forum. Urmia, Iran: Faculty of Veterinary Medicine, Urmia University; 2012. p. 181.
45. Sahadeva RPK, Leong SF, Chua KH, Tan CH, Chan HY, Tong EV, Wong SYW, Chan HK. Survival of commercial probiotic strains to pH and bile. Int Food Res J. 2011;18(4);1515–1522.
46. Pan X, Chen F, Wu T, Tang H, Zhao Z. The acid, bile tolerance and antimicrobial property of Lactobacillus acidophilus NIT. Food Control. 2009;20(6):598–602. doi: 10.1016/j.foodcont.2008.08.019.
47. Aiba Y, Nakano Y, Koga Y, Takahashi K, Komatsu Y. A highly acid‐resistant novel strain of Lactobacillus johnsonii No. 1088 has antibacterial activity, including that against helicobacter pylori, and inhibits gastrin‐mediated acid production in mice. Microbiologyopen. 2015;4(3):465–474.
48. Corcoran B, Stanton C, Fitzgerald GF, Ross RP. Survival of probiotic lactobacilli in acidic environments is enhanced in the presence of metabolizable sugars. Appl Environ Microbiol. 2005;71(6):3060–3067. doi: 10.1128/AEM.71.6.3060-3067.2005.
49. Conway P, Gorbach S, Goldin B. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci. 1987;70(1):1–12. doi: 10.3168/jds.S0022-0302(87)79974-3.
50. Begley M, Hill C, Gahan CG. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol. 2006;72(3):1729–1738. doi: 10.1128/AEM.72.3.1729-1738.2006.
51. Maragkoudakis PA, Zoumpopoulou G, Miaris C, Kalantzopoulos G, Pot B, Tsakalidou E. Probiotic potential of Lactobacillus strains isolated from dairy products. Int Dairy J. 2006;16(3):189–199. doi: 10.1016/j.idairyj.2005.02.009.
52. Di Ciaula A, Garruti G, Lunardi Baccetto R, Molina-Molina E, Bonfrate L, Wang DQ, Portincasa P. Bile acid physiology. Ann Hepatol. 2017:16(1):6-7.
53. Northfield T, McColl I. Postprandial concentrations of free and conjugated bile acids down the length of the normal human small intestine. Gut. 1973;14(7):513–518.
54. Tannock G, Munro K, Harmsen HJ, Welling GW, Smart J, Gopal PK. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosusDR20. Appl Environ Microbiol. 2000;66(6):2578–2588.
55. Goossens D, Jonkers D, Russel M, Stobberingh E, Van Den Bogaard A, StockbrUgger R. The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo‐controlled study on the onset and duration of effects. Aliment Pharmacol Ther. 2003;18(5):495–505. doi: 10.1046/j.1365-2036.2003.01708.x.
56. Vitali B, Minervini G, Rizzello CG, Spisni E, Maccaferri S, Brigidi P, Gobbetti M, Di Cagno R. Novel probiotic candidates for humans isolated from raw fruits and vegetables. Food Microbiol. 2012;31(1):116–125. doi: 10.1016/j.fm.2011.12.027.
57. Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr. 2001;73(2):399s–405s. doi: 10.1093/ajcn/73.2.399s.
58. Yuki N, Watanabe K, Mike A, Tagami Y, Tanaka R, Ohwaki M, Morotomi M. Survival of a probiotic, Lactobacillus casei strain Shirota, in the gastrointestinal tract: selective isolation from faeces and identification using monoclonal antibodies. Int J Food Microbiol. 1999;48(1):51–57.
59. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, von Wright A. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosusGG, after oral consumption. Appl Environ Microbiol. 1999;65(1):351–354.
60. Valeur N, Engel P, Carbajal N, Connolly E, Ladefoged K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol. 2004;70(2):1176–1181.
61. Smith TJ, Anderson D, Margolis LM, Sikes A, Young AJ. Persistence of Lactobacillus reuteri DSM17938 in the human intestinal tract: response to consecutive and alternate-day supplementation. J Am Coll Nutr. 2011;30(4):259–264.
62. Juge N. Microbial adhesins to gastrointestinal mucus. Trends Microbiol. 2012;20(1):30–39. doi: 10.1016/j.tim.2011.10.001.
63. Van Klinken BJ-W, Einerhand AWC, Duits LA, Makkink MK, Tytgat KMAJ, Renes IB, Verburg M, Büller HA, Dekker J. Gastrointestinal expression and partial cDNA cloning of murine Muc2. Am J Physiol Gastrointest Liver Physiol. 1999;276(1):G115–G124. doi: 10.1152/ajpgi.1999.276.1.G115.
64. Tytgat KM, Büller HA, Opdam FJ, Kim YS, Einerhand AW, Dekker J. Biosynthesis of human colonic mucin: muc2 is the prominent secretory mucin. Gastroenterology. 1994;107(5):1352–1363.
65. van Klinken BJ-W, Oussoren E, Weenink JJ, Strous GJ, Büller HA, Dekker J, Einerhand AW. The human intestinal cell lines Caco-2 and LS174T as models to study cell-type specific mucin expression. Glycoconj J. 1996;13(5):757–768.
66. Johansson ME, Larsson JMH, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host–microbial interactions. Proc Natl Acad Sci. 2011;108(Supplement 1):4659–4665. doi: 10.1073/pnas.1006451107.
67. Ouwehand AC, Salminen S. In vitro adhesion assays for probiotics and their in vivo relevance: a review. Microb Ecol Health Dis. 2003;15(4):175–184. doi: 10.1080/08910600310019886.
68. Crociani J, Grill JP, Huppert M, Ballongue J. Adhesion of different bifidobacteria strains to human enterocyte‐like Caco‐2 cells and comparison with in vivo study. Lett Appl Microbiol. 1995;21(3):146–148.
69. Chauviere G, Coconnier, MH, Kernéis SOPHIE, Fourniat J, Servin AL. Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. Microbiology. 1992;138(8):1689–1696.
70. Todoriki K, Mukai T, Sato S, Toba T. Inhibition of adhesion of food‐borne pathogens to Caco‐2 cells by Lactobacillus strains. J Appl Microbiol. 2001;91(1):154–159.
71. Bernet M-F, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut. 1994;35(4):483–489.
72. Luo Q, Kumar P, Vickers TJ, Sheikh A, Lewis WG, Rasko DA, Sistrunk J, Fleckenstein JM. Enterotoxigenic escherichia coli secretes a highly conserved mucin-degrading metalloprotease to effectively engage intestinal epithelial cells. Infect Immun. 2014;82(2):509–521. doi: 10.1128/IAI.01106-13.
73. Crossman LC, Chaudhuri RR, Beatson SA, Wells TJ, Desvaux M, Cunningham AF, Petty NK, Mahon V, Brinkley C, Hobman JL, et al. A commensal gone bad: complete genome sequence of the prototypical enterotoxigenic escherichia coli strain H10407. J Bacteriol. 2010;192(21):5822–5831. doi: 10.1128/JB.00710-10.
74. Taxt A, Aasland R, Sommerfelt H, Nataro J, Puntervoll P. Heat-stable enterotoxin of enterotoxigenic escherichia coli as a vaccine target. Infect Immun. 2010;78(5):1824–1831. doi: 10.1128/IAI.01397-09.
75. Gagnon M, Zihler Berner A, Chervet N, Chassard C, Lacroix C. Comparison of the Caco-2, HT-29 and the mucus-secreting HT29-MTX intestinal cell models to investigate salmonella adhesion and invasion. J Microbiol Methods. 2013;94(3):274–279. doi: 10.1016/j.mimet.2013.06.027.
76. Moellering RC, Jr. Emergence of enterococcus as a significant pathogen. Clin Infect Dis. 1992:1173–1176. doi: 10.1093/clinids/14.6.1173.
77. Diep DB, Straume D, Kjos M, Torres C, Nes IF. An overview of the mosaic bacteriocin pln loci from Lactobacillus plantarum. Peptides. 2009;30(8):1562–1574. doi: 10.1016/j.peptides.2009.05.014.
78. Da Silva Sabo S, Vitolo M, González JMD, Oliveira RPDS. Overview of Lactobacillus plantarum as a promising bacteriocin producer among lactic acid bacteria. Food Res Int. 2014;64:527–536. doi: 10.1016/j.foodres.2014.07.041.
79. Abee T, Klaenhammer T, Letellier L. Kinetic studies of the action of lactacin F, a bacteriocin produced by Lactobacillus johnsonii that forms poration complexes in the cytoplasmic membrane. Appl Environ Microbiol. 1994;60(3):1006–1013.
80. Ouwehand AC, Tuomola EM, Tölkkö S, Salminen S. Assessment of adhesion properties of novel probiotic strains to human intestinal mucus. Int J Food Microbiol. 2001;64(1):119–126.
81. Deplancke B, Gaskins HR. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr. 2001;73(6):1131S–1141S. doi: 10.1093/ajcn/73.6.1131S.
82. Mack D, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut. 2003;52(6):827–833.
83. Kumar P, Luo Q, Vickers TJ, Sheikh A, Lewis WG, Fleckenstein JM. EatA, an immunogenic protective antigen of enterotoxigenic Escherichia coli, degrades intestinal mucin. Infect Immun. 2014;82(2):500–508. doi: 10.1128/IAI.01078-13.
84. Van der Sluis M, De Koning BAE, De Bruijn ACJM, Velcich A, Meijerink JPP, Van Goudoever JB, Büller HA, Dekker J, Van Seuningen I, Renes IB, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006;131(1):117–129. doi: 10.1053/j.gastro.2006.04.020.
85. Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K, Augenlicht L. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science. 2002;295(5560):1726–1729. doi: 10.1126/science.1069094.
86. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330(4):257–262. doi: 10.1056/NEJM199401273300406.
87. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014;12(10):661. doi: 10.1038/nrmicro3344.
88. van Baarlen P, Troost F, van der Meer C, Hooiveld G, Boekschoten M, Brummer RJM, Kleerebezem M. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci. 2011;108(Supplement 1):4562–4569. doi: 10.1073/pnas.1000079107.
89. Smits HH, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TMM, Zaat BAJ, Yazdanbakhsh M, Wierenga EA, van Kooyk Y, et al. Selective probiotic bacteria induce IL-10–producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell–specific intercellular adhesion molecule 3–grabbing nonintegrin. J Allergy Clin Immunol. 2005;115(6):1260–1267. doi: 10.1016/j.jaci.2005.03.036.
90. Roselli M, Finamore A, Britti MS, Mengheri E. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic escherichia coli K88. Br J Nutr. 2006;95(6):1177–1184.
91. Saavedra J. Probiotics and infectious diarrhea. Am J Gastroenterol. 2000;95(1):S16–S18.
92. Huang JS, Bousvaros A, Lee JW, Diaz A, Davidson EJ. Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci. 2002;47(11):2625–2634.
93. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose–response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010;105(7):1636. doi: 10.1038/ajg.2010.11.
94. Guandalini S, Pensabene L, Zikri MA, Dias JA, Casali LG, Hoekstra H, Kolacek S, Massar K, Micetic-Turk D, Papadopoulou A, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30(1):54–60.
95. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics. 1991;88(1):90–97.
96. Saavedra JM, Bauman NA, Perman JA, Yolken RH, Saavedra JM, Bauman NA, Oung I. Feeding of bifidobacterium bifidum and streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. The Lancet. 1994;344(8929):1046–1049. doi: 10.1016/S0140-6736(94)91708-6.
97. Szajewska H, Skórka A, Ruszczyński M, Gieruszczak-Białek D. Meta‐analysis: lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther. 2007;25(8):871–881. doi: 10.1111/j.1365-2036.2007.03282.x.
98. Watson JT, Gayer M, Connolly MA. Epidemics after natural disasters. Emerging Infect Dis. 2007;13(1):1. doi: 10.3201/eid1301.060779.
99. Gilliland S, Walker D. Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce a hypocholesterolemic effect in humans. J Dairy Sci. 1990;73(4):905–911. doi: 10.3168/jds.S0022-0302(90)78747-4.
100. Natoli M, Leoni BD, D’Agnano I, Zucco F, Felsani A. Good Caco-2 cell culture practices. Toxicol In Vitro. 2012;26(8):1243–1246. doi: 10.1016/j.tiv.2012.03.009.
101. Hsieh PS, Tsai Y-C, Chen Y-C, Teh S-F, Ou C-M, King VA-E. Eradication of helicobacter pylori infection by the probiotic strains Lactobacillus johnsonii MH‐68 and L. salivarius ssp. salicinius AP‐32. Helicobacter. 2012;17(6):466–477. doi: 10.1111/j.1523-5378.2012.00992.x.
102. Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E, Mentis A. In vitro and in vivo inhibition of helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol. 2004;70(1):518–526.
103. Koren S, Walenz BP, Berlin K, Miller JR, Bergman NH, Phillippy AM. Canu: scalable and accurate long-read assembly via adaptive k-mer weighting and repeat separation. Genome Res. 2017;27:722–736.
104. Hyatt D, Chen G-L, LoCascio PF, Land ML, Larimer FW, Hauser LJ. Prodigal: prokaryotic gene recognition and translation initiation site identification. BMC Bioinformatics. 2010;11(1):119. doi: 10.1186/1471-2105-11-119.
105. Laslett D, Canback B. ARAGORN, a program to detect tRNA genes and tmRNA genes in nucleotide sequences. Nucleic Acids Res. 2004;32(1):11–16. doi: 10.1093/nar/gkh152.
106. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30(14):2068–2069. doi: 10.1093/bioinformatics/btu153.
107. Tomida S, Nguyen L, Chiu B-H, Liu J, Sodergren E, Weinstock GM, Li H. Pan-genome and comparative genome analyses of propionibacterium acnes reveal its genomic diversity in the healthy and diseased human skin microbiome. MBio. 2013;4(3):e00003–13. doi: 10.1128/mBio.00003-13.
108. Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870–1874. doi: 10.1093/molbev/msw054.
109. Li W, Godzik A. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics. 2006;22(13):1658–1659. doi: 10.1093/bioinformatics/btl158.
110. van Heel AJ, de Jong A, Montalbán-López M, Kok J, Kuipers OP. BAGEL3: automated identification of genes encoding bacteriocins and (non-) bactericidal posttranslationally modified peptides. Nucleic Acids Res. 2013;41(W1):W448–W453. doi: 10.1093/nar/gkt391.